June 11, 2020
ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA) released policy principles reaffirming the pharmaceutical distribution industry’s commitment to assisting the country and frontline healthcare providers during pandemics and public health emergencies.
HDA highlights four priority areas:
“COVID-19 has shown America’s pharmaceutical supply chain, powered by HDA distributors, to be resilient,” said HDA President and CEO Chester “Chip” Davis, Jr. “Armed with significant logistics expertise and strong relationships across the healthcare ecosystem, pharmaceutical distributors are a vital partner in our country’s response efforts — and HDA members will continue to do whatever it takes, in coordination with the public sector, to ensure the delivery of critical medicines and supplies to healthcare providers and their patients.”
View the principles document.
For additional information and resources on pharmaceutical distributors’ response to COVID-19, visit www.hda.org/covid19.
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.